235 related articles for article (PubMed ID: 30805731)
1. Cost-effectiveness of newborn screening for severe combined immunodeficiency.
Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME
Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731
[TBL] [Abstract][Full Text] [Related]
2. Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.
Clément MC; Mahlaoui N; Mignot C; Le Bihan C; Rabetrano H; Hoang L; Neven B; Moshous D; Cavazzana M; Blanche S; Fischer A; Audrain M; Durand-Zaleski I
J Allergy Clin Immunol; 2015 Jun; 135(6):1589-93. PubMed ID: 25840725
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
[TBL] [Abstract][Full Text] [Related]
4. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
[TBL] [Abstract][Full Text] [Related]
5. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
McGhee SA; Stiehm ER; McCabe ER
J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results.
Thomas C; Durand-Zaleski I; Frenkiel J; Mirallié S; Léger A; Cheillan D; Picard C; Mahlaoui N; Riche VP; Roussey M; Sébille V; Rabetrano H; Dert C; Fischer A; Audrain M
Clin Immunol; 2019 May; 202():33-39. PubMed ID: 30946917
[TBL] [Abstract][Full Text] [Related]
7. Newborn screening for severe combined immune deficiency (technical and political aspects).
Kobrynski L
Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):539-46. PubMed ID: 26485096
[TBL] [Abstract][Full Text] [Related]
8. Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency.
Lipstein EA; Vorono S; Browning MF; Green NS; Kemper AR; Knapp AA; Prosser LA; Perrin JM
Pediatrics; 2010 May; 125(5):e1226-35. PubMed ID: 20403930
[TBL] [Abstract][Full Text] [Related]
9. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time.
Quinn J; Orange JS; Modell V; Modell F
Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663
[TBL] [Abstract][Full Text] [Related]
10. Societal value of newborn screening for severe combined immune deficiency in Arkansas: An economic analysis.
Hays LH
Public Health Nurs; 2019 Jul; 36(4):541-544. PubMed ID: 30945355
[TBL] [Abstract][Full Text] [Related]
11. Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency.
Kubiak C; Jyonouchi S; Kuo C; Garcia-Lloret M; Dorsey MJ; Sleasman J; Zbrozek AS; Perez EE
J Allergy Clin Immunol Pract; 2014; 2(6):697-702. PubMed ID: 25439359
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge.
Narayen IC; Te Pas AB; Blom NA; van den Akker-van Marle ME
Eur J Pediatr; 2019 Jan; 178(1):97-103. PubMed ID: 30334077
[TBL] [Abstract][Full Text] [Related]
13. [Neonatal screening of severe combined immunodeficiencies].
Thomas C; Mirallié S; Pierres C; Dert C; Clément MC; Mahlaoui N; Durand-Zaleski I; Fischer A; Audrain M;
Arch Pediatr; 2015 Jun; 22(6):646-52. PubMed ID: 25896629
[TBL] [Abstract][Full Text] [Related]
14. Newborn screening for severe combined immunodeficiency: clinical and cost-effectiveness approaches.
Boyarchuk O; Yarema N; Kinash M; Chornomydz I
Pol Merkur Lekarski; 2021 Feb; 49(289):80-83. PubMed ID: 33713100
[TBL] [Abstract][Full Text] [Related]
15. Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening.
de Pagter AP; Bredius RG; Kuijpers TW; Tramper J; van der Burg M; van Montfrans J; Driessen GJ;
Eur J Pediatr; 2015 Sep; 174(9):1183-8. PubMed ID: 25875249
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK.
Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R
Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987
[TBL] [Abstract][Full Text] [Related]
17. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia.
Modell V; Knaus M; Modell F
Immunol Res; 2014 Oct; 60(1):145-52. PubMed ID: 24599744
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
19. The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry.
la Marca G; Giocaliere E; Malvagia S; Funghini S; Ombrone D; Della Bona ML; Canessa C; Lippi F; Romano F; Guerrini R; Resti M; Azzari C
J Pharm Biomed Anal; 2014 Jan; 88():201-6. PubMed ID: 24076575
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
